Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Access this article Similar content being viewed by others Data Availability The dataset supporting the findings of this study was derived from publicly available clinical trial records on ClinicalTrials.gov ( using predefined search and eligibility criteria
Tirzepatide is FDA-approved (as both Mounjaro and Zepbound), which places it in a more favorable category than unapproved compounds
Patients using SubMagna sublingual tirzepatide should work closely with their prescriber to monitor results and adjust dosing as needed
Market Size & Forecast 2025 Market Size: USD 8.64 billion 2034 Projected Market Size: USD 35.61 billion CAGR (2026-2034): 17.08% Dominating Region: North America Fastest-Growing Region: Asia Pacific The global direct-to-consumer (DTC) weight-loss medication market comprises a wide range of products categorized by drug type, including prescription medications such as GLP-1 receptor agonists, lipase inhibitors, combination therapies, and other pharmaceutical formulations
Their use does not imply endorsement by, affiliation with, or sponsorship by the trademark holders
US$ 27.47
US$ 22.37
US$ 25.13
US$ 26.67
US$ 22.78
US$ 28.76
